OBJECTIVES: To investigate the relationship between lysosome-associated protein transmembrane-4β-35 (LAPTM4B-35) and the clinicopathological features and prognosis of pancreatic carcinoma. METHODS: The level of LAPTM4B-35 protein was determined by semiquantitative immunohistochemistry in pancreatic carcinoma specimens. The relationship between LAPTM4B-35 level and prognosis was determined using univariate and multivariate analyses. RESULTS: A total of 98 patient samples were included. The presence of LAPTM4B-35 protein was confirmed in 77/98 (78.6%) patients and was significantly associated with tumour stage, degree of differentiation and pathological staging of pancreatic carcinoma after primary surgery. Patients with high LAPTM4B-35 levels had a poorer overall survival compared with patients with lower levels. Multivariate analysis showed that LAPTM4B-35 was an independent prognostic factor for overall survival. CONCLUSIONS: LAPTM4B-35 was found to be present at high levels in a large proportion of patients with pancreatic carcinoma, and was closely related to disease progression and poor prognosis. LAPTM4B-35 may represent a new molecular target for the clinical evaluation and treatment of pancreatic carcinoma.
MarrettLDEllisonLFDryerD: Canadian cancer statistics at a glance: mesothelioma. CMAJ2008; 178: 677–678.
4.
JemalASiegelRWardE: Cancer statistics, 2008. CA Cancer J Clin2008; 58: 71–96.
5.
LowenfelsABMaisonneuveP: Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol2006; 20: 197–209.
6.
WolffRA: Novel therapies for pancreatic cancer. Cancer J2001; 7: 349–358.
7.
HarrisJBrucknerH: Adjuvant and neoadjuvant therapies of pancreatic cancer: A review. Int J Gastrointest Cancer2001; 29: 1–8.
8.
LeeMXSaifMW: Screening for early pancreatic ductal adenocarcinoma: an urgent call!JOP2009; 10: 104–108.
9.
DaiHLiRWheelerT: Enhanced survival in perineural invasion of pancreatic cancer: an in vitro approach. Hum Pathol2007; 38: 299–307.
10.
MagistrelliPAntinoriACrucittiA: Prognostic factors after surgical resection for pancreatic carcinoma. J Surg Oncol2000; 74: 36–40.
11.
ShaoGZZhouRLZhangQY: Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene2003; 22: 5060–5069.
12.
ZhouLHeXDCuiQC: Expression of LAPTM4B-35: A novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma. Cancer Lett2008; 264: 209–217.
13.
MengFLuoCHuY: Overexpression of LAPTM4B-35 in cervical carcinoma: A clinicopathologic study. Int J Gynecol Pathol2010; 29: 587–593.
14.
MengFLYinMZSongHT: LAPTM4B-35 overexpression is an independent prognostic marker in endometrial carcinoma. Int J Gynecol Cancer2010; 20: 745–750.
15.
YangHXiongFXLinM: LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol2010; 136: 275–281.
16.
ZhouLHeXDChenJ: Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma. Eur J Cancer2007; 43: 809–815.
17.
LiuYZhangQYQianN: Relationship between LAPTM4B gene polymorphism and susceptibility of gastric cancer. Ann Oncol2007; 18: 311–316.
18.
MorrisDGMusatMCzirjákS: Differential gene expression in pituitary adenomas by oligonucleotide array analysis. Eur J Endocrinol2005; 153: 143–151.
19.
KasperGVogelAKlamanI: The human LAPTM4b transcript is upregulated in various types of solid tumours and seems to play a dual functional role during tumour progression. Cancer Lett2005; 224: 93–103.
YangYYangHMcNuttMA: LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma. Oncol Rep2008; 20: 1077–1083.
22.
YangHLinMXiongF: Combined lysosomal protein transmembrane 4 beta-35 and argininosuccinate synthetase expression predicts clinical outcome in hepatocellular carcinoma patients. Surg Today2011; 41: 810–817.
23.
TanACFanJBKarikariC: Allele-specific expression in the germline of patients with familial pancreatic cancer: an unbiased approach to cancer gene discovery. Cancer Biol Ther2008; 7: 135–144.
24.
BattyGDKivimakiMMorrisonD: Risk factors for pancreatic cancer mortality: extended follow-up of the original Whitehall study. Cancer Epidemiol Biomarkers Prev2009; 18: 673–675.
25.
ChappuisPOGhadirianPFoulkesWD: The role of genetic factors in the etiology of pancreatic adenocarcinoma: an update. Cancer Invest2001; 19: 65–75.
26.
LeungTKLeeCMWangFC: Difficulty with diagnosis of malignant pancreatic neoplasms coexisting with chronic pancreatitis. World J Gastroenterol2005; 11: 5075–5078.
27.
LiuXXiongFWeiX: LAPTM4B-35, a novel tetratransmembrane protein and its PPRP motif play critical roles in proliferation and metastatic potential of hepatocellular carcinoma cells. Cancer Sci2009; 100: 2335–2340.
28.
PengCZhouRLShaoGZ: Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma. World J Gastroenterol2005; 11: 2704–2708.
29.
ZhouLHeXDYuJC: Overexpression of LAPTM4B promotes growth of gallbladder carcinoma cells in vitro. Am J Surg2010; 199: 515–521.
30.
ZhouLHeXDYuJC: Overexpression of LAPTM4B-35 attenuates epirubucin-induced apoptosis of gallbladder carcinoma GBC-SD cells. Surgery2011; 150: 25–31.
31.
YangHXiongFWeiX: Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo. Cancer Lett2010; 294: 236–244.
32.
YangHXiongFQiR: LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma. J Surg Oncol2010; 101: 363–369.
